

David Van Duin

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/9471755/publications.pdf](https://exaly.com/author-pdf/9471755/publications.pdf)

Version: 2024-02-01

162
papers

10,178
citations

46744

46
h-index

36479

95
g-index

172
all docs

172
docs citations

172
times ranked

13206
citing authors

#	ARTICLE	IF	CITATIONS
1	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. <i>Clinical Infectious Diseases</i> , 2024, 78, 711-718.	5.6	6
2	Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant <i>Acinetobacter baumannii</i> Among Patients From Different Global Regions. <i>Clinical Infectious Diseases</i> , 2024, 78, 248-258.	5.6	10
3	<i>In vitro</i> activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant <i>Acinetobacter baumannii</i> collected in U.S. hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2024, 68, .	3.4	3
4	COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina. <i>Journal of Antimicrobial Chemotherapy</i> , 2024, 79, 859-867.	3.2	0
5	Duration of antibiotic treatment for acute graft pyelonephritis: What's the standard of care?. <i>Transplant Infectious Disease</i> , 2023, 25, .	1.6	1
6	Impact of childhood malnutrition and intestinal microbiota on MDR infections. <i>JAC-Antimicrobial Resistance</i> , 2023, 5, .	2.1	5
7	Utility of Urine Cultures During Febrile Neutropenia Workup in Hematopoietic Stem Cell Transplantation Recipients Without Urinary Symptoms. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.9	2
8	International Epidemiology of Carbapenemase-Producing <i>Escherichia coli</i> . <i>Clinical Infectious Diseases</i> , 2023, 77, 499-509.	5.6	9
9	Socioeconomic disparities in the prevalence of multidrug resistance in Enterobacterales. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 2068-2070.	2.0	3
10	Utilizing Ceftazidime/Avibactam Therapeutic Drug Monitoring in the Treatment of Neurosurgical Meningitis Caused by Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> and KPC-Producing Enterobacterales. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.9	3
11	Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. <i>American Journal of Transplantation</i> , 2022, 22, 279-288.	4.8	67
12	Resistance in Enterobacterales Is Higher Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 75, 28-34.	5.6	8
13	Clinical outcomes and bacterial characteristics of carbapenem-resistant <i>Klebsiella pneumoniae</i> complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 401-412.	8.8	152
14	Encephalitis Caused by Jamestown Canyon Virus in a Liver Transplant Patient, North Carolina, USA, 2017. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac031.	0.9	4
15	Considerations for the Use of Phage Therapy in Clinical Practice. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0207121.	3.4	181
16	Infectious Diseases Society of America Guidance on the Treatment of AmpC β -Lactamase-Producing Enterobacterales, Carbapenem-Resistant <i>Acinetobacter baumannii</i> , and <i>Stenotrophomonas maltophilia</i> Infections. <i>Clinical Infectious Diseases</i> , 2022, 74, 2089-2114.	5.6	311
17	Clinical challenges treating <i>Stenotrophomonas maltophilia</i> infections: an update. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac040.	2.1	60
18	An overview of COVID-19 in solid organ transplantation. <i>Clinical Microbiology and Infection</i> , 2022, 28, 779-784.	6.4	14

#	ARTICLE	IF	CITATIONS
19	Accessory Genomes Drive Independent Spread of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Clonal Groups 258 and 307 in Houston, TX. <i>MBio</i> , 2022, 13, e0049722.	4.3	20
20	Carbapenem-Resistant <i>Acinetobacter baumannii</i> in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. <i>MBio</i> , 2022, 13, e0275921.	4.3	37
21	Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I). <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab616.	0.9	26
22	Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR- <i>P. aeruginosa</i>). <i>Clinical Infectious Diseases</i> , 2022, 75, 187-212.	5.6	239
23	Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to <i>Pseudomonas aeruginosa</i> in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH) <i>TJ ETQq1 1 0.784314 rgBIB/Overl</i>	3.4	14
24	Carbapenemase-Encoding Gene Copy Number Estimator (CCNE): a Tool for Carbapenemase Gene Copy Number Estimation. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	4
25	Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106633.	3.3	54
26	Characteristics of community-acquired carbapenem-resistant Enterobacterales. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2763-2771.	3.2	11
27	Antimicrobial-resistant Enterobacterales colonization in people with HIV. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, .	2.1	5
28	Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. <i>MBio</i> , 2022, 13, .	4.3	10
29	Early appropriate diagnostics and treatment of MDR Gram-negative infections. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, .	2.1	22
30	A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.4	4
31	Predicting Risk of Multidrug-Resistant Enterobacterales Infections Among People With HIV. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	6
32	Clinical Impact of Ceftriaxone Resistance in <i>Escherichia coli</i> Bloodstream Infections: A Multicenter Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	7
33	Eravacycline Associated Hypofibrinogenemia: A Case Series of Transplant Patients With <i>Mycobacterium Abscessus</i> Infections and Review of Literature. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	2
34	Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005–2015. <i>Journal of Infectious Diseases</i> , 2021, 223, 2113-2123.	3.9	16
35	Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and <i>Achromobacter xylosoxidans</i> Infections. <i>Clinical Infectious Diseases</i> , 2021, 73, e1754-e1757.	5.6	30
36	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR- <i>P. aeruginosa</i>). <i>Clinical Infectious Diseases</i> , 2021, 72, e169-e183.	5.6	320

#	ARTICLE	IF	CITATIONS
37	Sulfonamides without trimethoprim in the treatment of <i>Nocardia</i> infections: A case report and literature review. <i>Transplant Infectious Disease</i> , 2021, 23, e13452.	1.6	5
38	Antibacterial Resistance Leadership Group 2.0: Back to Business. <i>Clinical Infectious Diseases</i> , 2021, 73, 730-739.	5.6	7
39	Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005–2015. <i>Aids</i> , 2021, 35, 1229-1239.	2.1	6
40	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR- <i>P. aeruginosa</i>). <i>Clinical Infectious Diseases</i> , 2021, 72, 1109-1116.	5.6	261
41	Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2053-2068.	3.1	56
42	Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. <i>Transplantation</i> , 2021, 105, e265-e266.	1.1	142
43	COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study. <i>American Journal of Transplantation</i> , 2021, 21, 2774-2784.	4.8	44
44	Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. <i>MSphere</i> , 2021, 6, e0027521.	3.1	39
45	Uncertainty in evaluating treatment outcomes in carbapenem-resistant <i>Acinetobacter baumannii</i> infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0142421.	3.4	3
46	A β -lactam siderophore antibiotic effective against multidrug-resistant <i>Pseudomonas aeruginosa</i> , <i>Klebsiella pneumoniae</i> , and <i>Acinetobacter</i> spp.. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113436.	5.7	16
47	Antimicrobial Resistance in Enterobacterales and Its Contribution to Sepsis in Sub-saharan Africa. <i>Frontiers in Medicine</i> , 2021, 8, 615649.	2.7	12
48	Genomic epidemiology of <i>Escherichia coli</i> isolates from a tertiary referral center in Lilongwe, Malawi. <i>Microbial Genomics</i> , 2021, 7, .	2.1	13
49	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. <i>Journal of Infectious Diseases</i> , 2021, 224, 657-666.	3.9	3
50	The BioWipe: a non-invasive method to detect intestinal carriage of multi-drug resistant gram-negative bacteria. <i>Journal of Chemotherapy</i> , 2021, , 1-3.	1.5	1
51	The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections. <i>Clinical Infectious Diseases</i> , 2020, 70, 1826-1833.	5.6	63
52	Polymyxin Resistance in <i>Klebsiella pneumoniae</i> : Complexity at Every Level. <i>Clinical Infectious Diseases</i> , 2020, 70, 2092-2094.	5.6	7
53	Multidrug-Resistant Bacteria in the Community. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 709-722.	4.1	98
54	Loss of daptomycin susceptibility in clinical <i>Staphylococcus epidermidis</i> infection coincided with variants in Walk. <i>Evolution, Medicine and Public Health</i> , 2020, 2020, 219-224.	2.5	1

#	ARTICLE	IF	CITATIONS
55	The impact of the COVID-19 pandemic on antimicrobial resistance: a debate. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa053.	2.1	28
56	A β -Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5990-6002.	6.6	24
57	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 731-741.	8.8	200
58	ARGONAUT II Study of the <i>In Vitro</i> Activity of Plazomicin against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.4	13
59	Combined Medical and Surgical Management of Hepatic Mucormycosis in an Adult with Acute Myeloid Leukemia: Case Report and Review of the Literature. <i>Mycopathologia</i> , 2019, 184, 155-158.	3.0	1
60	Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders. <i>American Journal of Hematology</i> , 2019, 94, 1396-1412.	4.2	16
61	Sex-Based Differences in Inpatient Burn Mortality. <i>World Journal of Surgery</i> , 2019, 43, 3035-3043.	1.4	17
62	Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Producing KPC. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	31
63	Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria. <i>F1000Research</i> , 2019, 8, 121.	1.6	29
64	508. Gentamicin Non-susceptibility is Associated with Persistence of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in the Urinary Tract. <i>Open Forum Infectious Diseases</i> , 2019, 6, S246-S246.	0.9	0
65	622. The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS). <i>Open Forum Infectious Diseases</i> , 2019, 6, S289-S289.	0.9	0
66	2276. Clinical Epidemiology of the Carbapenem-Resistant Enterobacteriaceae (CRE) Epidemic in Colombia: A Multicenter Prospective Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S779-S779.	0.9	1
67	625. Genomic Epidemiology of Carbapenem-Resistant Enterobacteriaceae from Colombia: A Prospective Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S290-S290.	0.9	2
68	636. Genome Epidemiology of Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAb) in the United States. <i>Open Forum Infectious Diseases</i> , 2019, 6, S295-S295.	0.9	2
69	Carbapenemase-producing organisms in solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 490-496.	1.5	4
70	The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy351.	0.9	12
71	Sequential, Multiple-Assignment, Randomized Trials for Comparing Personalized Antibiotic Strategies (SMART-COMPASS). <i>Clinical Infectious Diseases</i> , 2019, 68, 1961-1967.	5.6	11
72	ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β -Lactamases and Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	88

#	ARTICLE	IF	CITATIONS
73	Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria. <i>F1000Research</i> , 2019, 8, 121.	1.6	18
74	Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. <i>Clinical Infectious Diseases</i> , 2018, 66, 163-171.	5.6	514
75	Relebactam Is a Potent Inhibitor of the KPC-2 β -Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.4	78
76	Evaluation of Sensititre Broth Microdilution Plate for determining the susceptibility of carbapenem-resistant <i>Klebsiella pneumoniae</i> to polymyxins. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 89-92.	1.8	11
77	Burn injury outcomes in patients with pre-existing diabetic mellitus: Risk of hospital-acquired infections and inpatient mortality. <i>Burns</i> , 2018, 44, 272-279.	2.0	14
78	Chinaâ€™United States Research Collaborations in Antimicrobial Resistance. <i>Clinical Infectious Diseases</i> , 2018, 67, S142-S145.	5.6	3
79	Reply to Elamin et al. <i>Clinical Infectious Diseases</i> , 2018, 67, 982-983.	5.6	1
80	Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by <i>Klebsiella pneumoniae</i> Carbapenemaseâ€™Producing <i>Klebsiella pneumoniae</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy054.	0.9	12
81	Endemic Mycoses in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 667-685.	4.1	23
82	Colistin Resistance in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> : Laboratory Detection and Impact on Mortality. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw805.	5.6	153
83	Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know. <i>Virulence</i> , 2017, 8, 379-382.	4.4	26
84	From VAP to VAE: Implications of the New CDC Definitions on a Burn Intensive Care Unit Population. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 867-869.	2.0	5
85	Improved Survival of Patients With Extensive Burns. <i>Journal of Burn Care and Research</i> , 2017, 38, 187-193.	0.5	38
86	NDM-5 and OXA-181 Beta-Lactamases, a Significant Threat Continues To Spread in the Americas. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.4	70
87	Life-threatening Skin Disorders Treated in the Burn Center. <i>Clinics in Plastic Surgery</i> , 2017, 44, 597-602.	1.6	5
88	Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. <i>Clinical Infectious Diseases</i> , 2017, 64, S30-S35.	5.6	117
89	Even Better Than the Real Thing? Xenografting in Pediatric Patients with Scald Injury. <i>Clinics in Plastic Surgery</i> , 2017, 44, 651-656.	1.6	9
90	Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by <i>Pseudomonas aeruginosa</i> Compared to Other Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.4	128

#	ARTICLE	IF	CITATIONS
91	Clinical presentation and outcomes of norovirus infection in intestinal allograft compared to native intestine. <i>Transplant Infectious Disease</i> , 2017, 19, e12692.	1.6	3
92	Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy. <i>Drugs</i> , 2017, 77, 615-628.	11.0	112
93	A Prolonged Outbreak of KPC-3-Producing <i>Enterobacter cloacae</i> and <i>Klebsiella pneumoniae</i> Driven by Multiple Mechanisms of Resistance Transmission at a Large Academic Burn Center. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.4	72
94	Reply to Macesic et al. <i>Clinical Infectious Diseases</i> , 2017, 65, 703-704.	5.6	0
95	Systems-based Practice in Burn Care. <i>Clinics in Plastic Surgery</i> , 2017, 44, 935-942.	1.6	7
96	Improving Research Enrollment of Severe Burn Patients. <i>Journal of Burn Care and Research</i> , 2017, 38, e807-e813.	0.5	3
97	Risk Factors for Healthcare-Associated Infections in Adult Burn Patients. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 1441-1448.	2.0	19
98	The global epidemiology of carbapenemase-producing <i>Enterobacteriaceae</i> . <i>Virulence</i> , 2017, 8, 460-469.	4.4	654
99	Bacterial Infections After Burn Injuries: Impact of Multidrug Resistance. <i>Clinical Infectious Diseases</i> , 2017, 65, 2130-2136.	5.6	245
100	A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant <i>Enterobacteriaceae</i> . <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx157.	0.9	22
101	Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections in Patients on Renal Replacement Therapy. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx216.	0.9	6
102	Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytes. <i>PLoS ONE</i> , 2017, 12, e0184164.	2.5	18
103	Hospital Readmissions in Patients With Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 281-288.	2.0	24
104	Serious infections in the elderly. , 2016, , 331-343.		1
105	Multidrug-Resistant Bacteria in the Community. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 377-390.	4.1	408
106	Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β -Lactam/ β -Lactamase Inhibitor Combinations. <i>Clinical Infectious Diseases</i> , 2016, 63, 234-241.	5.6	449
107	Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in a Child with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5627-5630.	3.4	24
108	Predictors of persistent diarrhea in norovirus enteritis after solid organ transplantation. <i>Clinical Transplantation</i> , 2016, 30, 1488-1493.	1.6	23

#	ARTICLE	IF	CITATIONS
109	Timeline of health care-associated infections and pathogens after burn injuries. <i>American Journal of Infection Control</i> , 2016, 44, 1511-1516.	2.4	66
110	Vancomycin-resistant Enterococcal Bloodstream Infections in Hematopoietic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies: Impact of Daptomycin MICs of 3 to 4 mg/L. <i>Clinical Therapeutics</i> , 2016, 38, 2468-2476.	2.3	17
111	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 <i>Klebsiella pneumoniae</i> Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. <i>Genome Biology and Evolution</i> , 2016, 8, 2036-2043.	2.6	28
112	Next-Generation Sequencing and Comparative Analysis of Sequential Outbreaks Caused by Multidrug-Resistant <i>Acinetobacter baumannii</i> at a Large Academic Burn Center. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1249-1257.	3.4	35
113	Increasing Rates of Fluoroquinolone Resistance in <i>Escherichia coli</i> Blood and Urinary Isolates in Stem Cell Transplant and Hematologic Malignancy Populations. <i>Pathogens and Immunity</i> , 2016, 1, 234.	3.4	17
114	Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1203-1211.	3.2	48
115	Residence in Skilled Nursing Facilities Is Associated with Tigecycline Nonsusceptibility in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 942-948.	2.0	22
116	Impact of Daptomycin Minimum Inhibitory Concentration (MIC) on Outcomes of Patients with Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT) Recipients with Vancomycin-Resistant Enterococci (VRE) Bloodstream Infection (BSI). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S277.	2.0	0
117	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4375-4378.	3.4	25
118	Rates of Hospital-Associated Respiratory Infections and Associated Pathogens in a Regional Burn Center, 2008-2012. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 601-603.	2.0	9
119	Commentary: Outbreak of Colistin-Resistant, Carbapenemase-Producing <i>Klebsiella pneumoniae</i> : Are We at the End of the Road?. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3116-3117.	4.4	39
120	Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Urinary Tract Infection following Solid Organ Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 553-557.	3.4	42
121	Genomic and Transcriptomic Analyses of Colistin-Resistant Clinical Isolates of <i>Klebsiella pneumoniae</i> Reveal Multiple Pathways of Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 536-543.	3.4	191
122	Healthcare-Associated Infections among Patients in a Large Burn Intensive Care Unit: Incidence and Pathogens, 2008-2012. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 1304-1306.	2.0	27
123	Reduction in Central Line-Associated Bloodstream Infections in Patients with Burns. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 1066-1068.	2.0	21
124	Genome Sequences of Two Carbapenemase-Resistant <i>Klebsiella pneumoniae</i> ST258 Isolates. <i>Genome Announcements</i> , 2014, 2, .	0.8	10
125	Population Structure of KPC-Producing <i>Klebsiella pneumoniae</i> Isolates from Midwestern U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4961-4965.	3.4	78
126	Functional Polymorphisms in the Gene Encoding Macrophage Migration Inhibitory Factor Are Associated With Gram-Negative Bacteremia in Older Adults. <i>Journal of Infectious Diseases</i> , 2014, 209, 764-768.	3.9	23

#	ARTICLE	IF	CITATIONS
127	Complex prosthetic joint infections due to carbapenemase-producing <i>Klebsiella pneumoniae</i> : a unique challenge in the era of untreatable infections. <i>International Journal of Infectious Diseases</i> , 2014, 25, 73-78.	3.3	56
128	Surveillance of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> : Tracking Molecular Epidemiology and Outcomes through a Regional Network. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4035-4041.	3.4	136
129	The impact of multidrug resistance on outcomes in ventilator-associated pneumonia. <i>American Journal of Infection Control</i> , 2014, 42, 542-545.	2.4	26
130	A High Performance Biomarker Detection Method for Exhaled Breath Mass Spectrometry Data. <i>Springer Proceedings in Mathematics and Statistics</i> , 2014, , 207-216.	0.0	1
131	Selecting suitable solid organ transplant donors: Reducing the risk of donor-transmitted infections. <i>World Journal of Transplantation</i> , 2014, 4, 43.	1.6	30
132	Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 115-120.	1.8	291
133	OqxAB, a Quinolone and Olaquinox Efflux Pump, Is Widely Distributed among Multidrug-Resistant <i>Klebsiella pneumoniae</i> Isolates of Human Origin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4602-4603.	3.4	57
134	Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients. <i>Cleveland Clinic Journal of Medicine</i> , 2013, 80, 225-233.	1.4	146
135	Postoperative Fever and Infection in Immunosuppressed Patients. , 2013, , 253-259.		0
136	Endovascular Infections Caused by <i>Histoplasma capsulatum</i> : A Case Series and Review of the Literature. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 640-645.	2.5	20
137	Diagnostic Challenges and Opportunities in Older Adults With Infectious Diseases. <i>Clinical Infectious Diseases</i> , 2012, 54, 973-978.	5.6	75
138	<i>Staphylococcus Aureus</i> Bacteremia in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2012, 93, 1045-1050.	1.1	47
139	Experience with Fosfomycin for Treatment of Urinary Tract Infections Due to Multidrug-Resistant Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5744-5748.	3.4	168
140	Increased Rate of Spontaneous Bacterial Peritonitis Among Cirrhotic Patients Receiving Pharmacologic Acid Suppression. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 422-427.	4.7	94
141	Challenges of Interferon- γ Release Assay Conversions in Serial Testing of Health-care Workers in a TB Control Program. <i>Chest</i> , 2012, 142, 55-62.	0.8	85
142	Clinical Presentation and Management of Histoplasmosis in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 265-270.	2.9	12
143	Treatment and outcomes in carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infections. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 357-362.	1.8	151
144	Extreme alkaline phosphatase elevation associated with tigecycline. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 952-953.	3.2	4

#	ARTICLE	IF	CITATIONS
145	Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy. <i>Emerging Infectious Diseases</i> , 2011, 17, 754-756.	4.3	22
146	Age-Associated Decrease in TLR Function in Primary Human Dendritic Cells Predicts Influenza Vaccine Response. <i>Journal of Immunology</i> , 2010, 184, 2518-2527.	0.8	481
147	Nontuberculous mycobacterial blood stream and cardiac infections in patients without HIV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 67, 286-290.	1.8	17
148	Age-Associated Defect in Human TLR-1/2 Function. <i>Journal of Immunology</i> , 2007, 178, 970-975.	0.8	316
149	Prevaccine Determination of the Expression of Costimulatory B7 Molecules in Activated Monocytes Predicts Influenza Vaccine Responses in Young and Older Adults. <i>Journal of Infectious Diseases</i> , 2007, 195, 1590-1597.	3.9	154
150	Toll-Like Receptors in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1438-1444.	2.9	115
151	Triggering TLR signaling in vaccination. <i>Trends in Immunology</i> , 2006, 27, 49-55.	6.7	332
152	<i>Blastomyces dermatitidis</i> produces melanin in vitro and during infection. <i>FEMS Microbiology Letters</i> , 2004, 239, 187-193.	1.8	44
153	Effects of Voriconazole on <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2014-2020.	3.4	71
154	Melanization of <i>Cryptococcus neoformans</i> and <i>Histoplasma capsulatum</i> Reduces Their Susceptibilities to Amphotericin B and Caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3394-3400.	3.4	200
155	Seizures in the Critically Ill: The Role of Imipenem. <i>Epilepsia</i> , 2001, 42, 1590-1593.	4.6	51
156	Participant Diversity in United States Randomized Controlled Trials of Antibacterials for <i>Staphylococcus aureus</i> Infections, 2000-2021. <i>Clinical Infectious Diseases</i> , 0, , .	5.6	1
157	Clinical characteristics and genome epidemiology of <i>Stenotrophomonas maltophilia</i> in Japan. <i>Journal of Antimicrobial Chemotherapy</i> , 0, , .	3.2	0
158	Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales. <i>Journal of Antimicrobial Chemotherapy</i> , 0, , .	3.2	0
159	Cytomegalovirus Disease: Fine-Tuning Clinical Trial Enrollment and Standardization. <i>Clinical Infectious Diseases</i> , 0, , .	5.6	0
160	ARGONAUT-III and -V: susceptibility of carbapenem-resistant <i>Klebsiella pneumoniae</i> and multidrug-resistant <i>Pseudomonas aeruginosa</i> to the bicyclic boronate β -lactamase inhibitor taniborbactam combined with cefepime. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	3.4	0
161	A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	3.4	0
162	Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections. <i>Journal of Antimicrobial Chemotherapy</i> , 0, , .	3.2	0